Antithrombotic therapy in patients undergoing coronary angioplasty

Chest

Volumn 108, Issue 4 SUPPL., 1995, Pages 486S-501S

  Popma, J J ^a   Coller, B S ^a   Ohman, E M ^a   Bittl, J A ^a   Weitz, J ^a   Kuntz, R E ^a   Leon, M B ^a  

^a Cardiology Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DEXTRAN 40; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR; HEPARIN; MONOCLONAL ANTIBODY; TICLOPIDINE; WARFARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DILATATION; DRUG MECHANISM; HEPARINIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; POSTOPERATIVE THROMBOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SURGICAL ANATOMY; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

EID: 0028788077     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.108.4_Supplement.486S     Document Type: Conference Paper

References (133)

1. Myler RK Shaw RE Stertzer SH Lesion morphology and coronary angioplasty: current experience and analysis J Am Coll Cardiol 19 1992 1641 1652
2. Detre KM Holmes DR Holubkov R Incidence and consequences of periprocedural occlusion: the 1985–1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry Circulation 82 1990 739 750
3. De Feyter PJ van den Brand M Jaarman G Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management and follow-up Circulation 83 1991 927 936
4. Lincoff AM Popma JJ Ellis SG Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic, and therapeutic profile J Am Coll Cardiol 19 1992 926 935
5. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330:956-61
6. Ellis SG Roubin GS King SB III Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty Circulation 77 1988 372 379
7. Ryan TJ Faxon DP Gunnar RP Guidelines for percutaneous transluminal coronary angioplasty J Am Coll Cardiol 12 1988 529 545
8. Tenaglia AN Fortin DF Califf RM Predicting the risk of abrupt closure after angioplasty in an individual patient J Am Coll Cardiol 24 1994 1004 1011
9. Mintz GS Kovach JA Javier SP Geometric remodeling is the predominant mechanism of late lumen loss after coronary angioplasty [abstract] Circulation 88 1993 I 654
10. Chuang YC Popma JJ Foegh M Effect of non-target lesion events on the predictive value of 6 month angiography for late (12 month) clinical outcome after PTCA [abstract] J Am Coll Cardiol 25 1995 94 95A
11. Topol EJ Califf RM Weisman HF Randomised trial of coronary intervention with antibody against platelet Ilb/IIIa integrin for reduction of clinical restenosis: results at 6 months Lancet 343 1994 881 886
12. Elliott JM Berdan LG Holmes DR One-year follow-up in the coronary angioplasty versus excisional atherectomy trial (CAVEAT I) Circulation 91 1995 2158 2166
13. Detre K Holubkov R Kelsey S Percutaneous transluminal coronary angioplasty in 1985–1986 and 1977–1981: the National Heart, Lung, and Blood Institute Registry N Engl J Med 318 1988 265 270
14. Schwartz L Bourassa MG Lesperance J Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty N Engl J Med 318 1988 1714 1719
15. Ferguson JJ Dougherty KG Gaos CM Relation between procedural activated clotting time and outcome after percutaneous transluminal coronary angioplasty J Am Coll Cardiol 23 1994 1061 1065
16. Kuntz RE Piana R Pomerantz RM Changing incidence and management of abrupt closure following coronary intervention in the new device era Cathet Cardiovasc Diagn 27 1992 183 190
17. Fishman DL Leon MB Baim DS A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease N Engl J Med 331 1994 496 501
18. Serruys PW de Jaegere P Kiemeneij F A comparison of balloon-expandable-stent implantation in patients with coronary artery disease N Engl J Med 331 1994 489 495
19. Topol EJ Leya F Pinkerton CA A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease N Engl J Med 329 1993 221 227
20. Badimon L Badimon JJ Galvez A Influence of arterial wall damage and wall shear rate on platelet deposition: ex vivo study in a swine model Arteriosclerosis 6 1986 312 320
21. Wilentz JR Sanborn TA Haudenschild CC Platelet accumulation in experimental angioplasty: time course in relation to cardiovascular injury Circulation 75 1987 636 642
22. White CW Chaitman B Lassar TA Antiplatelet agents are effective in reducing the immediate complications of PTCA: results of the ticlopidine multicenter trial [abstract] Circulation 76 1987 IV-400
23. Barnathan ES Schwartz JS Taylor L Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty Circulation 76 1987 125 134
24. Mufson L Black A Roubin G A randomized trial of aspirin in PTCA: effect of high versus low dose aspirin on major complications and restenosis [abstract] J Am Coll Cardiol 11 1988 236 A
25. Lembo NJ Black AJR Roubin GS Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty Am J Cardiol 65 1990 422 426
26. Timmermans C Vrolix M Vanhaecke J Ridogrel in the setting of percutaneous transluminal coronary angioplasty Am J Cardiol 68 1991 463 466
27. Knudtson ML Flintoft VF Roth DL Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty J Am Coll Cardiol 15 1990 691 697
28. Gasperetti CM Gonias SL Gimple LW Platelet activation during coronary angioplasty in humans Circulation 88 1993 2728 2734
29. Anderson HV Kirkeeide RL Krishnaswami A Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody J Am Coll Cardiol 23 1994 1031 1037
30. Ruggeri ZM. Receptor-specific antiplatelet therapy Circulation 80 1989 1920 1922
31. Ruoslahti E Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins Science 238 1987 491 497
32. Phillips DR Charo IF Parise LV The platelet membrane glycoprotein Ilb-IIIa complex Blood 71 1988 831 843
33. Ellis SG Tcheng JE Navetta FI Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty Coron Artery Dis 4 1993 167 175
34. 2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein Ilb/IIIa in patients with unstable angina pectoris J Clin Invest 86 1990 651 659
35. Kleiman NS Ohman EM Califf RM Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study J Am Coll Cardiol 22 1993 381 389
36. Simoons ML de Boer MJ van den Brand MJBM Randomized trial of GP Ilb/IIIa platelet receptor blocker in refractory unstable angina Circulation 89 1994 596 603
37. Tcheng JE Ellis SG George BS Pharmacodynamics of chimeric glycoprotein Ilb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty Circulation 90 1994 1757 1764
38. Sutton JM Anderson K. Body weight and heparin dosing influence bleeding complications with c7E3 antiplatelet antibody [abstract] Circulation 88 1993 I 209
39. Lefkovits J Ivanhoe R Anderson K Platelet Ilb/IIIa receptor inhibition during PTCA for acute myocardial infarction: Insights from the EPIC trial [abstract] Circulation 90 1994 I 564
40. Lincoff AM Califf RM Anderson K Striking clinical benefit with platelet GP Ilb/IIIa inhibition by c7E3 among patients with unstable angina: outcome in the EPIC Trial [abstract] Circulation 90 1994 1 21
41. Lefkovits J Anderson K Weisman H Increased risk of non-Q-wave MI following DCA: evidence for a platelet dependent mechanism from the EPIC trial [abstract] Circulation 90 1994 I 214
42. Lincoff AM Tcheng JE Bass TA A multicenter, randomized, double-blind pilot trial of standard versus low dose weight-adjusted heparin in patients treated with the platelet GP Ilb/IIIa receptor antibody c7E3 during percutaneous coronary angioplasty [abstract] J Am Coll Cardiol 25 1995 80 81A
43. Harrington RA Rios G Kleiman NS Platelet function during integrelin administration in coronary angioplasty [abstract] Circulation 88 1993 1 319
44. Tcheng JE Kleiman NS Harrington RA Outcome of patients treated with the GP Ilb/IIIa inhibitor integrelin during coronary angioplasty: results of the IMPACT study [abstract] Circulation 88 1993 I 595
45. Peerlinck K De Lepeleire I Goldberg M MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man Circulation 88 1993 1512 1517
46. Kereiakes D Kleiman N Ambrose J A dosing study in high-risk PTCA of MK-383, a platelet Ilb/IIIa antagonist [abstract] Circulation 90 1994 1 21
47. Topol EJ Bonan R Jewitt D Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty Circulation 87 1993 1622 1629
48. Grayburn PA Willard JE Brincker ME In vivo thrombus formation on a guidewire during intravascular ultrasound imaging: evidence for inadequate heparinization Cathet Cardiovasc Diagn 23 1991 141 143
49. Bull BS Korman RA Huse WM Heparin therapy during extracorporeal circulation: I. Problems inherent in existing protocols J Thorac Cardiovasc Surg 69 1975 674 684
50. Young JA Kisher CT Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by the activated clotting time and the appearance of fibrin monomer Ann Thorac Surg 26 1976 231 234
51. Dougherty KG Gaos CM Bush HS Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin Cathet Cardiovasc Diagn 26 1992 260 263
52. Bowers J Ferguson JJ. The use of activated clotting times to monitor heparin therapy during and after interventional procedures Clin Cardiol 17 1994 357 361
53. Ferguson JJ. All ACTs are not created equal [editorial] Texas Heart Inst J 19 1992 1 3
54. Laskey MAL Deutsch E Hirshfeld JW Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus Am J Cardiol 65 1990 179 182
55. Laskey MAL Deutsch E Barnathan E Influence of heparin on percutaneous transluminal coronary angioplasty outcomes in unstable angina pectoris Am J Cardiol 65 1990 1425 1429
56. Hillegass WB Brott BC Haura EB Patient-specific heparin dosing during angioplasty [abstract] J Am Coll Cardiol 25 1995 391 A
57. Brack MJ More RS Hubner PJ The effect of low dose nitroglycerin on plasma heparin concentrations and activated partial thromboplastin times Blood Coagul Fibrinolysis 4 1993 183 186
58. Hubbub MA Haft JL Heparin resistance induced by intravenous nitroglycerin Arch Intern Med 147 1987 857 860
59. Miller RD. Heparin resistance prior to cardiopulmonary bypass Anesthesiology 64 1986 504 507
60. Marmur JD Sharma SK Kantrowitz NE Angiographically complex lesions are associated with increased levels of thrombin generation and activity following PTCA [abstract] J Am Coll Cardiol 25 1995 155 A
61. Narins CR Hillegass WB Nelson CL Activated clotting time predicts abrupt closure risk during coronary angioplasty [abstract] J Am Coll Cardiol 23 1994 470 A
62. Hillegass WB Brott BC Narins CR Predictors of blood loss and bleeding complications after angioplasty [abstract] J Am Coll Cardiol 23 1994 69 A
63. Popma JJ Satler LF Pichard AD Vascular complications after balloon and new device angioplasty Circulation 88 1993 1569 1578
64. Ogilby JD Kopelman HA Klein LW Adequate heparinization during PTCA: assessment using activated clotting times Cathet Cardiovasc Diagn 18 1989 206 209
65. Serruys PW Deckers JW Close P. A double-blind, randomized, heparin controlled trial evaluating acute and long-term efficacy of r-hirudin (CGP 39393) in patients undergoing coronary angioplasty [abstract] Circulation 90 1994 I 394
66. Strony J Bittl JA Deutsch E Hirulog vs heparin during percutaneous transluminal coronary angioplasty in patients with post-infarction angina: results of the myocardial infarction arm of the Hirulog Angioplasty Trial [abstract] J Am Coll Cardiol 25 1995 357 A
67. Ellis SG Roubin GS Wilentz J Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty Am Heart J 117 1989 777 782
68. Friedman HZ Cragg DR Glazier SM Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty J Am Coll Cardiol 24 1994 1214 1219
69. McGarry TF Gottlieb RS Morganroth J The relationship of anticoagulation level and complications after successful percutaneous transluminal angioplasty Am Heart J 123 1992 1445 1451
70. Lefkovits J Topol EJ. Direct thrombin inhibitors in cardiovascular medicine Circulation 90 1994 1522 1536
71. Sharma GVRK Lapsley D Vita JA Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris Am J Cardiol 72 1993 1357 1360
72. Lidon RM Theroux P Juneau M Initial experience with a direct antithrombin, hirulog, in unstable angina: anticoagulant, antithrombotic, and clinical effects Circulation 88 1993 1495 1501
73. Cannon CP Maraganore JM Loscalzo J Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease Am J Cardiol 71 1993 778 782
74. Van den Bos AA Deckers JW Heyndrickx GR Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty Circulation 88 1993 2058 2066
75. Serruys PW Fox KAA Herrman JRR Recombinanthirudin (CGP 39393) reduces the incidence of major adverse cardiac events, reported within the first 96 hours post-angioplasty in unstable patients (Braunwald classification) pre-treated by heparin [abstract] J Am Coll Cardiol 25 1995 80 A
76. Schwartz RS Holmes DR Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms J Am Coll Cardiol 20 1992 1284 1293
77. Jang Y Lincoff AM Plow EF Cell adhesion molecules in coronary artery disease J Am Coll Cardiol 24 1994 1591 1601
78. Popma JJ Califf RM Topol EJ. Clinical trials of restenosis after coronary angioplasty Circulation 84 1991 1426 1436
79. Herrman JR Hermans WRM Vos J Pharmacological approaches to the prevention of restenosis following angioplasty Drugs 46 1993 259 262
80. Thornton MA Gruentzig AR Hollman J Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study Circulation 69 1984 721 727
81. Taylor RR Gibbons FA Cope GD Effects of low-dose aspirin on restenosis after coronary angioplasty Am J Cardiol 68 1991 874 878
82. Schwartz L Lesperance J Bourassa MG The role of antiplatelet agents in modifying the extent of restenosis following percutaneous transluminal coronary angioplasty Am Heart J 119 1990 232 236
83. Bussman W-D Kaltenbach M Kober G The Frankfurt experience in restenosis after coronary angioplasty Am J Cardiol 60 1987 48B 49B
84. Darius H Sellig S Belz GG Aspirin 500 mg/d is superior to 100 mg and 40 mg for prevention of restenosis following PTCA [abstract] Circulation 90 1994 I 651
85. Serruys PW Rutsch W Heyndrickx GR Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade: a randomized, double-blind, placebo-controlled trial Circulation 84 1991 1568 1580
86. Savage MP Goldberg S Macdonald RG Multi-hospital Eastern Atlantic restenosis trial II: a placebo-controlled trial of thromboxane blockade in the prevention of restenosis following coronary angioplasty Am Heart J 122 1991 1239 1244
87. 2 blockade on events after PTCA: M-Heart II [abstract] J Am Coll Cardiol 19 1992 209 A
88. Finci L Hofling B Ludwig B Sulotroban during and after coronary angioplasty: a double-blind, placebo controlled study Kardiologie 78 1989 50 54
89. Serruys PW Klein W Tijssen JPG Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty: a multicenter randomized double-blind placebo-controlled trial Circulation 88 1993 1588 1601
90. Raizner A Hollman J Demke D Beneficial effects of ciprostene in PTCA: a multicenter, randomized, controlled trial [abstract] Circulation 78 1988 II-290
91. Raizner AE Hollman J Abukhalil J Ciprostene for restenosis revisited: quantitative analysis of angiograms [abstract] J Am Coll Cardiol 21 1993 321A
92. Dehmer GJ Popma JJ ven den Berg EK Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids N Engl J Med 319 1988 733 740
93. Bairati I Roy L Meyer F. Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty Circulation 85 1992 950 956
94. Milner MR Gallino RA Leffingwell A Usefulness of fish oil supplements in preventing clinical evidence of restenosis after percutaneous transluminal coronary angioplasty Am J Cardiol 64 1989 294 299
95. Grigg LE Kay TWH Valentine PA Determinants of restenosis and lack of effect of dietary supplementation with eicosopentaenoic acid on the incidence of coronary artery restenosis after angioplasty J Am Coll Cardiol 13 1989 665 672
96. Reis GJ Sipperly ME McCabe CH Randomised trial of fish oil for prevention of restenosis after coronary angioplasty Lancet 2 1989 177 181
97. Franzen D Schannwell M Oette K A prospective, randomized, and double-blind trial of the effect of fish oil on the incidence of restenosis following PTCA Cathet Cardiovasc Diagn 28 1993 301 310
98. Kaul U Sanghvi S Bahl VK Fish oil supplements for prevention of restenosis after coronary angioplasty Int J Cardiol 35 1992 87 93
99. Leaf A Jorgensen MB Jacobs AK Do fish oils prevent restenosis after coronary angioplasty? Circulation 90 1994 2248 2257
100. Cairns JA Gill JB Morton B Enoxaparine and Maxepa for the prevention of angioplasty restenosis (EMPAR) [abstract] Circulation 90 1994 I 651
101. Faxon DP Spiro TE Minor S Low molecular weight heparin in prevention of restenosis after angioplasty: results of the enoxaparin restenosis (ERA) trial Circulation 90 1994 908 914
102. Urban P Buller N Fox K Lack of effect of warfarin on the restenosis rate or on clinical outcome after balloon coronary angioplasty Br Heart J 60 1988 485 488
103. Hearn JA King SB Douglas JS Clinical and angiographic outcomes after coronary stenting for acute or threatened closure after percutaneous coronary angioplasty: initial results with a balloon-expandable, stainless steel stent Circulation 88 1993 2455 2457
104. Roubin GS Cannon AD Agrawal SK Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty Circulation 85 1992 916 927
105. Schatz RA. New challenges in coronary stenting J Invas Cardiol 7 1995 43 A
106. Goldberg SL Colombo A Nakamura S. The benefit of intracoronary ultrasound on the deployment of Palmaz-Schatz stents J Am Coll Cardiol 24 1994 996 1003
107. Hall P Colombo A Almagor Y. Preliminary experience with intravascular ultrasound-guided Palmaz-Schatz coronary stenting: the acute and short-term results on a consecutive series of patients J Interv Cardiol 7 1994 141 159
108. Colombo A Hall P Nakamura S Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound Circulation 91 1995 1676 1688
109. Hall P Nakamura S Maiello L Clinical and angiographic outcome after Palmaz-Schatz stent implantation guided by intravascular ultrasound J Invas Cardiol 7 1995 12A 22A
110. Fernandez-Aviles F Alonso J Duran JM Absence of bleeding and subacute occlusion after Palmaz-Schatz coronary stenting using a new antithrombotic regimen [abstract] J Am Coll Cardiol 25 1995 196 A
111. Blasini R Mudra H Schuhlen H Intravascular ultrasound guided optimized emergency coronary Palmaz-Schatz stent placement without post-procedural systemic anticoagulation [abstract] J Am Coll Cardiol 25 1995 197 A
112. Colombo A Nakamura S Hall P A prospective study of Gianturco-Roubin coronary stent implantation without anticoagulation [abstract] J Am Coll Cardiol 25 1995 50 A
113. Russo R Schatz RA Sklar MA Ultrasound guided coronary stent placement without prolonged systemic anticoagulation [abstract] J Am Coll Cardiol 25 1995 50 A
114. Colombo A Nakamura S Hall P A prospective study of Wiktor coronary stent implantation without anticoagulation [abstract] J Am Coll Cardiol 25 1995 239 A
115. Van Belle E McFadden EP Bauters C Combined antiplatelet therapy without anticoagulation: an effective alternative to prevent subacute thrombosis after coronary stenting [abstract] J Am Coll Cardiol 25 1995 197 A
116. Lablanche J-M Grollier G Danchin N Full anticoagulation therapy without anticoagulation after coronary stenting [abstract] J Am Coll Cardiol 25 1995 181 A
117. Barragan P Silverstri M Sainsous J Prevention of subacute occlusion after coronary stenting with ticlopidine regimen without intravascular ultrasound guided stenting [abstract] J Am Coll Cardiol 25 1995 182 A
118. Buszman P Clague J Gibbs S Improved post stent management: high gain and low risk [abstract] J Am Coll Cardiol 25 1995 182 A
119. Carvalho H Fajadet J Jordan C A lower rate of complications after Gianturco-Roubin stenting using a new antiplatelet and anticoagulation protocol [abstract] 90 1994 I 125
120. Elias J Monassier JP Puel J Medtronic-Wiktor implantation without coumadin: hospital outcome [abstract] Circulation 90 1994 I 124
121. Barragan P Sainsous J Silverstri M Ticlopidine and subcutaneous heparin as an alternative regimen following coronary stenting Cathet Cardiovasc Diagn 32 1994 133 138
122. Blengino S Maiello L Hall P Randomized trial of coronary stent implantation without anticoagulation: aspirin versus ticlopidine [abstract] Circulation 90 1994 I 124
123. Jordan C Carvalho H Fajadet J Reduction of subacute thrombosis after stenting using a new anticoagulation protocol [abstract] Circulation 90 1994 I 125
124. Morice M-C. Advances in post stenting medication J Invas Cardiol 7 1994 32A 35A
125. Wong SC Popma J Mintz G Preliminary results from the Reduced Anticoagulation in Saphenous Vein Graft (RAVES) Trial [abstract] Circulation 90 1994 1 125
126. Brown RI Aldridge HE Schwartz L The use of detran-40 during percutaneous transluminal coronary angioplasty: a report of three cases of anaphylactoid reactions—one near fatal Cathet Cardiovasc Diagn 11 1985 591 595
127. Klugmann S Salvi A Valente M Coronary artery spasm after administration of dextran 40: implications concerning percutaneous transluminal coronary angioplasty Am Heart J 111 1986 1202 1204
128. Taylor MA Di Blasi SL Bender RM Adult respiratory distress syndrome complicating intravenous infusion of low-molecular weight dextran Cathet Cardiovasc Diagn 32 1994 249 253
129. Hass WK Easton JD Adams HP A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study Group N Engl J Med 321 1989 501 507
130. Rodriquez JN Femandez-Jurado A Dieguez JC Ticlopidine and severe aplastic anemia Am J Hematol 47 1994 332
131. Bellavance A. Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular events: the Ticlopidine Aspirin Stroke Study Stroke 25 1994 1452 1457
132. Page Y Tardy B Seni F Thrombotic thrombocytopenic purpura related to ticlopidine Lancet 337 1991 774 776
133. Haynes RB Sandler RS Larson EB A critical appraisal of ticlopidine, a new antiplatelet agent: effectiveness and clinical indications for prophylaxis of atherosclerotic events Arch Intern Med 152 1992 1376 1380